Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study
Loading...
Date
2019-07
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
BMC
Series Info
BMC CHEMISTRY;Volume: 13 Article Number: UNSP 82
Scientific Journal Rankings
Abstract
Highly sensitive and selective liquid chromatography/tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous estimation of the recently approved oral hypoglycemic mixture; metformin (MET) and canagliflozin (CFZ) in human plasma using propranolol HCl (PPL) and tadalafil (TDF) as internal standards (IS), respectively. Analytes were extracted using protein precipitation induced by acetonitrile then liquid-liquid extraction was performed using ethyl acetate. Reversed phase HPLC was carried out using C18 analytical column (50 mm x 4.6 mm i.d., 5 mu m) with a simple isocratic mobile phase composed of 0.1% formic acid and acetonitrile (60:40, v/v). Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 -> 60.1, m/z 462.3 -> 191.0, m/z 260.2 -> 183.0 and m/z 390.2 -> 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode. The analysis was carried out within 5 min over a linear concentration range of 50-5000 ng/mL for MET and 10-1000 ng/mL for CFZ. The method was validated in accordance with the FDA guidelines for bioanalytical method. All obtained recoveries were higher than 90.0% while the accuracy was in the range of 88.14-113.05% and the relative standard deviation was below 10.0% for all investigated drugs by the proposed method. The achieved promising results has allowed for the successful application of the developed LC-MS/MS method to a pharmacokinetic study of the target drugs after their oral administration to Egyptian healthy volunteers. The pharmacokinetic study was accomplished after the agreement of the ethics committee.
Description
MSA Google Scholar
Accession Number: WOS:000475529700001
Accession Number: WOS:000475529700001
Keywords
VALIDATION, DERIVATIZATION, PHARMACODYNAMICS, RAT PLASMA, COMBINATION THERAPY, LIQUID-CHROMATOGRAPHY, TYPE-2 DIABETES-MELLITUS, COTRANSPORTER 2 INHIBITOR, TANDEM MASS-SPECTROMETRY, Pharmacokinetic study, Human plasma, HPLC-MS/MS, Metformin, Canagliflozin
Citation
Valsamakis G, Kumar S (2000) Insulin action enhancers for the management of Type 2 diabetes mellitus. Expert Opin Pharmacother 7:1413–1421 CrossRefGoogle Scholar 2. Bell DS (2004) Type 2 diabetes mellitus: what is the optimal treatment regimen? Am J Med 116:23S–29S CrossRefGoogle Scholar 3. Riddle M (2000) Combining sulfonylureas and other oral agents. Am J Med 108:15S–22S CrossRefGoogle Scholar 4. Rosenstock J, Chuck L, González-Ortiz M, Merton K, Craig J, Capuano G, Qiu R (2016) Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve Type 2 biabetes. Diabetes Care 39:353–362 CrossRefGoogle Scholar 5. Drug bank. Drug monograph canagliflozin. 2017. http://www.drugbank.ca/drugs/DB08907/. Accessed 25 July 2017 6. Elkinson S, Scott LJ (2013) Canagliflozin: first global approval. Drugs 73:979–988 CrossRefGoogle Scholar 7. Rosiak M, Grzeszczak S, Kosior DA, Postuła M (2014) Emerging treatments in type 2 diabetes: focus on canagliflozin. Ther Clin Risk Manage 10:683–689 Google Scholar 8. Janssen Pharmaceuticals Inc. Invokana TM (canagliflozin) tablets, for oral use: US prescribing information. 2013. http://www.janssenmd.com/pdf/invokana/PI-INVOKANA.pdf. Accessed 19 Dec 2016 9. Lajara R (2014) The potential role of sodium glucose co transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother 15:2565–2585 CrossRefGoogle Scholar 10. USP Convension Inc. The United States Pharmacopeia 39, National Formulary 34, Rockvill, Maryland. 2016 Google Scholar 11. Sweetman SC (2009) Martindale, the complete drug reference, 36th edn. Pharmaceutical Press, London Google Scholar 12. Keith CR, John RW (1996) Metformin: a new oral biguanide. Clin Ther 18:360–371 CrossRefGoogle Scholar 13. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ (2002) Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51:2074–2081 CrossRefGoogle Scholar 14. Dudhe PB, Kamble MC (2016) RP-HPLC method development and validation for the determination of canagliflozin in human plasma. Int J Pharm Tech Res 9:174–181 Google Scholar 15. Iqbal M, Ezzeldin E, Al-Rashood KA, Asiri YA, Rezk NL (2015) A simple and sensitive HPLC assay with a fluorescence detector for determination of canagliflozin in human plasma. Talanta 132:29–36 CrossRefGoogle Scholar 16. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, Rothenberg PL (2013) Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 53:601–610 CrossRefGoogle Scholar 17. Devineni D, Vaccaro N, Polidori D, Rusch S, Wajs E (2014) Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther 36:698–710 CrossRefGoogle Scholar 18. Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D, Vandebosch A, Rusch S, Stieltjes H, Wajs E (2015) Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Ther 37:610–628 CrossRefGoogle Scholar 19. Inagaki N, Kondo K, Yoshinari T, Ishii M, Sakai M, Kuki H, Furihata K (2014) Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment. Clin Drug Invest 34:731–742 CrossRefGoogle Scholar 20. Kobuchi S, Yano K, Ito Y, Sakaeda T (2016) A validated LC–MS/MS for the determination of canagliflozin in lower volume of rat plasma: application to pharmacokinetic studies in rats. Biomed Chromatogr 30:1549–1555 CrossRefGoogle Scholar 21. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CV). FDA Guidance for industry: bioanalytical method validation. 2013 Google Scholar 22. European Medicines Agency EMEA/CHMP/EWP/192217/2009, Committee for Medicinal Products for Human Use. Draft guidance on validation of bioanalytical methods. 2009 Google Scholar 23. Somarouthu VS, Nageswara RP, Bhavani PKB, Pitchaimuthu SB (2018) A novel and rapid LC–MS/MS assay method for the determination of canagliflozin in human plasma by solid phase extraction technique and its application to a pharmacokinetic study. Future J Pharm Sci 4:131–138 CrossRefGoogle Scholar 24. AbuRuz S, Millership J, McElnay J (2003) Determination of metformin in plasma using a new ion pair solid phase extraction technique and ion pair liquid chromatography. J Chromatogr B Anal Technol Biomed Life Sci 798:203–209 CrossRefGoogle Scholar 25. Tache F, David V, Farca A, Medvedovici A (2001) HPLC-DAD determination of Metformin in human plasma using derivatization with p-nitrobenzoyl chloride in a biphasic system. Microchem J 68:13–19 CrossRefGoogle Scholar 26. David V, Barcutean C, Sora I, Medvedovici A (2005) Determination of metformin in plasma samples by HPLC-DAD based on plasma derivatization and precipitation with acetic anhydride. Rev Roum Chim 50:269–276 Google Scholar 27. Ranetti MC, Ionescu M, Hinescu L, Ionică E, Anuţa V, Ranetti AE, Stecoza CE, Mircioiu C (2009) Validation of a HPLC method for the simultaneous analysis of metformin and gliclazide in human plasma. Farmacia 57:728–735 Google Scholar 28. Yardimci C, Ozaltin N, Gurlek A (2007) Simultaneous determination of rosiglitazone and metformin in plasma by gradient liquid chromatography with UV detection. Talanta 72:1416–1422 CrossRefGoogle Scholar 29. Mistri HN, Jangid AG, Shrivastav PS (2007) Liquid chromatography tandem mass spectrometry method for simultaneous determination of antidiabetic drugs metformin and glyburide in human plasma. J Pharm Biomed Anal 45:97–106 CrossRefGoogle Scholar 30. Zhong G, Bi H, Zhou S, Chen X, Huang M (2005) Simultaneous determination of metformin and gliclazide in human plasma by liquid chromatography–tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy volunteers. J Mass Spectrom 40:1462–1471 CrossRefGoogle Scholar 31. Kumar PP, Murthy TE, Basaveswara Rao MV (2015) Development, validation of liquid chromatography–tandem mass spectrometry method for simultaneous determination of rosuvastatin and metformin in human plasma and its application to a pharmacokinetic study. J Adv Pharm Technol Res 6:118–124 CrossRefGoogle Scholar 32. Liu A, Coleman SP (2009) Determination of metformin in human plasma using hydrophilic interaction liquid chromatography–tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 877:3695–3700 CrossRefGoogle Scholar 33. Wang Y, Tang Y, Gu J, Fawcett JP, Bai X (2004) Rapid and sensitive liquid chromatography–tandem mass spectrometric method for the quantitation of metformin in human plasma. J Chromatogr B Anal Technol Biomed Life Sci 808:215–219 CrossRefGoogle Scholar 34. Marques MA, Ade SS, Pinto OW, Barroso PT, Pinto DP, Ferreira-Filho M, Werneck-Barroso E (2007) Simple and rapid method determination for metformin in human plasma using high performance liquid chromatography tandem mass spectrometry: application to pharmacokinetic studies. J Chromatogr B Anal Technol Biomed Life Sci 852:308–316